Trial Profile
A Phase I study of TSU-68 in combination with S-1 in patients with advanced hepatocellular carcinoma who are not candidates for conventional therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Jun 2016
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Orantinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 01 Dec 2015 New trial record